Hagemeyer Group - NanoBiotechnology

Key terms: Molecular Imaging, Drug Delivery, Nanotechnology, Biotechnology

2023 group L-R: Thirimadura Mendis, Rong Xu, Edwina Jap, Christoph Hagemeyer, Peije Russell, Saeedreza Zeibishirejini, Bamlaku Walie. Absent: Tuan Nguyen, Be'eri Niego

Group Leader

Research Overview

Our main theme is the development of "bio-better" antibodies with added functionality for the treatment of thrombosis, inflammation, diabetes and cancer. Using specifically modified recombinant antibodies we can deliver small molecules, therapeutic oligos, proteins and nanoparticles with high precision and reduced adverse effects. We can achieve this with a new bio-enzymatic conjugation method allowing site-specific attachment of nano-sized delivery scaffolds without affecting antibody function. We are also active in the molecular imaging area. Using targeted natural nanoparticles, we would like to significantly increase the number of imaging labels per antibody in MRI and PET/SPECT as well as photoacoustic and fluorescence imaging. This can increase the detection limit of current approaches.

Project Opportunities

• Targeted virus particles for gene therapy
• Single-chain antibody-targeted nanoparticles for therapy and diagnosis
• Recombinant agents for efficient and safe anticoagulation as well as thrombolysis

For current project opportunity descriptions please visit our Honours page

Current Grants

• ARC LIEF Grant LE240100038 (2024): A multimodal infrared, raman and fluorescence submicron imaging microscope. CIs: Wood, Arandiyan, Grace, Wang, Simonov, Conn, Blanch, Greene, Gleadow, Stoddart, Hagemeyer.
• ARC Grant IC230100046 (2024-28): ARC ITTC for the Development of Advanced Radiochemical Technologies (DART). CIs: Robinson, Donnelly, Rendina, McIntosh, Hagemeyer, Tuck, Andrews, Alt, Ritchie, Turner, Chan, Aulsebrook, Hutton, White, Rutledge, New, Ackermann.
• National Heart Foundation Vanguard Grant 106859 (2023-2024): Molecular imaging of cardiac fibrosis in atrial fibrillation, heart failure and myocardial infarction. PIs: Niego, Alt, Hagemeyer.
• Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA) together with Helmholtz Zentrum Dresden Rossendorf, Germany (2021-2025). Monash CIs: Hagemeyer, Aulsebrook, Alt, Andrews, Egan, Jupp, Ritchie, Robinson, Tuck.
• Plan 111 in collaboration with Shandong University, Ministry of Science and Technology of China (2020-24): Discipline innovation of colloid and interface chemistry. PIs: Caruso, Besenbacher, Tieu, Qiao, De Geest, Lee, Eastoe, Nicolas, Hagemeyer, Thurecht, Ashokkumar.
• NHMRC Ideas Grant APP1181440 (2020-24): Self-regulated, glucose-responsive nanomaterials for smart insulin delivery. CIs: Hagemeyer, Cavalieri.

Research projects

Research publications